Phathom Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Phathom Pharmaceuticals reported significant revenue growth in 2025 driven by VOQUEZNA sales, while narrowing net losses and securing new financing to support its path to operating profitability by Q3 2026.
NASDAQ
Phathom Pharmaceuticals announces its FY2024 results, emphasizing the commercial launch and growing demand for VOQUEZNA.
NASDAQ
Phathom Pharmaceuticals files an amendment to its 10-K report, primarily to correct certifications and provide additional details on its stock and financial structure.
NASDAQ
10-K: Phathom Pharmaceuticals Reports Full Year 2023 Results, Initiates Commercial Launch of VOQUEZNA
Phathom Pharmaceuticals initiated the commercial launch of VOQUEZNA for Erosive GERD and H. pylori in Q4 2023, while also advancing its pipeline with a focus on Non-Erosive GERD and Eosinophilic Esophagitis.